Clinical trial NCT02464514: Macronutrient Regulation of Ghrelin and Peptide YY
Official title: Investigation of the Developmental, Nutritional and Hormonal Regulation of Ghrelin in Children With Prader-Willi Syndrome (PWS) and Children With Hypothalamic-Derived Obesity: Macronutrient Regulation Sub-study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Prader Willi Syndrome
Keywords: Obesity
Orexigen
Insulin
Leptin
Adiponectin
Growth hormone replacement
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: Canadian Institutes of Health Research (CIHR)
name: Foundation for Prader-Willi Research
name: Stollery Children's Hospital Foundation
name: Alberta Diabetes Institute
name: Sarah W. Stedman Nutrition and Metabolism Center
name: American Diabetes Association
name: Duke Children's Miracle Network
name: National Center for Research Resources (NCRR)
First posted: 2015-06-08
Enrollment: 28
Sex: ALL
Minimum age (years): 5
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The hyperghrelinemia of children with PWS provides a unique model by which to explore the hormonal and metabolic effects of orexigenic hormones in normal and pathologic conditions. An important question to be addressed by this proposed research includes the macro-nutrient regulation of ghrelin and PYY in obese children and children with PWS. As ghrelin antagonists are considered potential future anti-obesity agents, it is essential to gain understanding of the developmental, nutritional and hormonal regulation of this important orexigenic hormone in children.

Detailed description: Obesity continues to be a prevalent health concern affecting every race of the American population. Studies show that obese children are likely to become obese adults. Also, recent studies report significant years of life lost due to the impact of being an obese adult . Thus, insights into the pathogenesis of childhood obesity and preventative measures are needed to combat the inevitable increase in worldwide incidence of obesity and its associated co-morbidities.

Ghrelin is a 28 amino acid acylated peptide which is an endogenous ligand of the growth hormone secretagogue receptor (GHS-R), a hypothalamic G-protein-coupled receptor. Enteroendocrine cells (X/A-like cells) of the stomach are the major site of ghrelin synthesis, although a minor proportion of ghrelin synthesis occurs in other sites such as the hypothalamus, pituitary, duodenum, jejunum and lung. Secreted in response to meals, ghrelin stimulates feeding through activation of anabolic neurons in the hypothalamic arcuate nucleus that co-express neuropeptide Y (NPY) and agouti-related protein (Agrp). Ghrelin relays its information from the GI tract to specific nuclei in the hypothalamus via the gastric afferent vagal nerve.

Studies in rodents support the premise that ghrelin is involved in energy balance. In humans, physiological levels of ghrelin influence energy homeostasis in humans.The rise in plasma ghrelin concentrations during fasting may play a role in meal initiation and body weight regulation.

Nearly all other forms of obesity are associated with low ghrelin levels. Paradoxically, researchers discovered that ghrelin levels in adults and children with PWS are 3-5 times higher than those in age- and BMI-matched controls. Hyperghrelinemia may thus play a causal role in the hyperphagia and obesity of PWS.

The hyperghrelinemia of children with PWS provides a unique model by which to explore the hormonal and metabolic effects of orexigenic hormones in normal and pathologic condtions. An important question to be addressed by this proposed research includes the macro-nutrient regulation of ghrelin in normal children and children with PWS. As ghrelin antagonists are considered potential future anti-obesity agents, it is essential to gain understanding of the developmental, nutritional and hormonal regulation of this important orexigenic hormone in children.

Eligibility criteria: Inclusion Criteria:

1. Diagnosis of PWS confirmed by chromosome analysis (i.e. interstitial deletion of paternally-derived chromosome 15Q, uniparental maternal disomy or other chromosome 15 abnormalities) or normal control
2. Subjects with simple obesity
3. Ages 5 years to 17 years
4. Written informed consent and assent obtained and willingness to comply with the study schedule and procedures.
5. Free T4, TSH values in the normal range (either endogenous or with thyroxine replacement)

Exclusion Criteria:

1. Patients with any other clinically significant disease that would have an impact on body composition including diabetes mellitus, chronic inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders
2. Concomitant use of an investigational drug in the past year
3. Patients with an active malignancy
4. Parent or legal guardian unable to provide informed consent.

Primary outcomes:
measure: Change in ghrelin levels
timeFrame: 4 hours
measure: Change in PYY concentrations
timeFrame: 4 hours
Secondary outcomes:
measure: Fasting Insulin-like growth factor 1 (IGF-1) levels
timeFrame: Baseline
measure: Neuropeptide Y (NPY)
timeFrame: Baseline
measure: Gastric inhibitory polypeptide (GIP)
timeFrame: Baseline
measure: Glucagon-like peptide-1 (GLP-1)
timeFrame: Baseline
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: University of Alberta
name: Andrea Haqq, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Duke University
name: Michael Freemark, MD
role: STUDY_DIRECTOR
References:
citation: Gumus Balikcioglu P, Balikcioglu M, Muehlbauer MJ, Purnell JQ, Broadhurst D, Freemark M, Haqq AM. Macronutrient Regulation of Ghrelin and Peptide YY in Pediatric Obesity and Prader-Willi Syndrome. J Clin Endocrinol Metab. 2015 Oct;100(10):3822-31. doi: 10.1210/jc.2015-2503. Epub 2015 Aug 10.